AYTU BIOPHARMA, INC Deferred Tax Liabilities, Deferred Expense, Capitalized Research and Development Costs
AYTU BIOPHARMA, INC (AYTU) had Deferred Tax Liabilities, Deferred Expense, Capitalized Research and Development Costs of $0 as of 2016-06-30, per its 10-K filed 2016-09-01.
Discontinued › Notes › Income Taxes › Components of Deferred Tax Assets and Liabilities
us-gaap:DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts · last filed 2016-09-01
- 2016-06-30: Deferred Tax Liabilities, Deferred Expense, Capitalized Research and Development Costs $0.00.
- 2015-06-30: Deferred Tax Liabilities, Deferred Expense, Capitalized Research and Development Costs $2.78M.
- 2014-06-30: Deferred Tax Liabilities, Deferred Expense, Capitalized Research and Development Costs $2.78M.
| Period end | Deferred Tax Liabilities, Deferred Expense, Capitalized Research and Development Costs |
|---|---|
| 2016-06-30 | $0.00 10-K · filed 2016-09-01 |
| 2015-06-30 | $2.78M 10-K · filed 2016-09-01 |
| 2014-06-30 | $2.78M 10-K · filed 2015-09-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NextCure, Inc. (NXTC) | United States | $0.024B | -0.15 |
| TherapeuticsMD, Inc. (TXMD) | United States | $0.024B | -117.87 |
| ARTELO BIOSCIENCES, INC. (ARTL) | United States | $0.023B | |
| KYNTRA BIO, INC. (KYNB) | United States | $0.028B | 0.17 |
| Transcode Therapeutics, Inc. (RNAZ) | United States | $0.029B | -0.12 |
| Cocrystal Pharma, Inc. (COCP) | United States | $0.022B | |
| Hepion Pharmaceuticals, Inc. (HEPA) | United States | $0.029B | -0.62 |
| ATOSSA THERAPEUTICS, INC. (ATOS) | United States | $0.021B | -0.52 |
| IGC Pharma, Inc. (IGC) | United States | $0.029B | -5.98 |
| Neuphoria Therapeutics Inc. (NEUP) | United States | $0.020B | -1.77 |